金石亚药：全资二级子公司取得药品注册证书

Group 1 - The core point of the article is that Jinshi Yiyao has received approval for its glucosamine sulfate capsule from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] - Jinshi Yiyao's revenue composition for the first half of 2025 is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1] - As of the report date, Jinshi Yiyao has a market capitalization of 4.8 billion yuan [1]